靜脈輸注。

Intravenous (IV) infusion.

0.9% 氯化鈉 (NS) 靜脈輸注液或 5% 葡萄糖 (D5W) 靜脈輸注液。

0.9% Sodium Chloride (NS) infusion or 5% Dextrose (D5W) infusion.

1 毫克小瓶應以 1.1 毫升無菌注射用水泡製；4 毫克小瓶應以 4 毫升無菌注射用水泡製。泡製後溶液每毫升含 1 毫克 topotecan。加入稀釋液後，達最終稀釋濃度25-50 mcg/mL

Reconstitute the 1 mg vial with 1

每次給藥應以 30 分鐘的時間靜脈輸注。

1. 本藥品具細胞毒性，調劑與給藥應遵循化療安全處理規範。2. 外滲風險：本藥通常被視為刺激劑（Irritant），外滲可能導致組織發炎或損傷；若發生外滲，應立即停止輸注，保留針頭以抽回藥液，並依院內外滲處置流程進行（如冷敷）。3. 避光：未配製前的藥粉應儲存在原包裝中以避光；稀釋後的輸注液在一般室內光線下雖具穩定性，但在給藥期間仍建議避免直接強光照射。4. 無須使用特殊過濾器。5. 調劑後應檢查有無微粒或變色。

1. This drug is cytotoxic; preparation and administration must follow hazardous drug handling procedures. 2. Extravasation risk: Topotecan is generally considered an irritant; extravasation may cause tissue inflammation or injury. If extravasation occurs, stop infusion immediately, leave the needle in place to aspirate any remaining drug, and manage according to institutional protocols (e.g., cold compresses). 3. Light protection: Vials of lyophilized powder should be stored in the original carton to protect from light. Diluted solutions are stable in ambient light, but exposure to direct strong light during administration should be avoided. 4. No special filter is required. 5. Inspect for particulate matter or discoloration after preparation.